Market Cap 10.40B
Revenue (ttm) 1.98B
Net Income (ttm) 83.59M
EPS (ttm) N/A
PE Ratio 19.71
Forward PE 19.77
Profit Margin 4.23%
Debt to Equity Ratio 0.41
Volume 883,504
Avg Vol 1,330,340
Day's Range N/A - N/A
Shares Out 222.29M
Stochastic %K 96%
Beta 0.66
Analysts Sell
Price Target $52.36

Company Profile

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 31 77 355 6600
Address:
Hulsterweg 82, Venlo, Netherlands
ZacksResearch
ZacksResearch Sep. 15 at 1:35 PM
$QGEN secures key CE-IVDR certification — will the stock’s momentum continue? 🚀 QIAGEN’s expanded QIAstat-Dx Panel broadens CNS infection coverage with 16 targets, strengthening its Molecular Diagnostics biz. The launch of this enhanced panel is expected in September 2025. With a 5% earnings yield against the industry’s -22.8%, it’s a promising outlook. Discover the potential impact on QGEN here 👉 https://www.zacks.com/stock/news/2751329/qgen-stock-gains-from-ce-ivdr-certification-for-qiastat-dx-portfolio?cid=sm-stocktwits-2-2751329-body-12357&ADID=SYND_STOCKTWITS_TWEET_2_2751329_BODY_12357
0 · Reply
ZacksResearch
ZacksResearch Sep. 15 at 12:35 PM
$QGEN just got a major boost 🚀 The full QIAstat-Dx portfolio is now CE-IVDR certified — strengthening its diagnostics arm and giving the stock a lift. See why this certification could be a game-changer 👉 https://www.zacks.com/stock/news/2751329/qgen-stock-gains-from-ce-ivdr-certification-for-qiastat-dx-portfolio?cid=sm-stocktwits-2-2751329-teaser-12355&ADID=SYND_STOCKTWITS_TWEET_2_2751329_TEASER_12355
0 · Reply
nikitatrades
nikitatrades Sep. 11 at 1:41 PM
$QGEN CFO: Strong H1 growth (6-7%) outpacing tools sector. Raising FY guidance. Key products QuantiFERON (20+ qtrs double-digit growth) & QIAstat driving performance. New sample prep launches (QIAsymphony Connect) coming. Margin target (31%) likely achieved by '26, ahead of schedule. 🧪 #Qiagen #Investing
0 · Reply
ZacksResearch
ZacksResearch Sep. 3 at 2:21 PM
$QGEN launches QIAstat-Dx Rise — enhancing diagnostics capabilities! 🚀 The FDA-cleared system offers automated, real-time PCR detection with minimal hands-on time, boosting testing capacity for hospitals and labs. With shares edging up 0.9% post-announcement, this momentum could continue. Discover how QGEN is expanding its diagnostics reach 👉 https://www.zacks.com/stock/news/2746540/qiagen-stock-may-benefit-from-the-us-clearance-of-qiastat-dx-rise?cid=sm-stocktwits-2-2746540-body-10705&ADID=SYND_STOCKTWITS_TWEET_2_2746540_BODY_10705
0 · Reply
ZacksResearch
ZacksResearch Sep. 3 at 1:20 PM
$QGEN could be gearing up for a catalyst move 🚀 The stock may benefit as the QIAstat-Dx Rise just secured US clearance — a major regulatory milestone. See the full investment angle here 👉 https://www.zacks.com/stock/news/2746540/qiagen-stock-may-benefit-from-the-us-clearance-of-qiastat-dx-rise?cid=sm-stocktwits-2-2746540-teaser-10664&ADID=SYND_STOCKTWITS_TWEET_2_2746540_TEASER_10664
0 · Reply
DonCorleone77
DonCorleone77 Sep. 2 at 10:23 AM
$QGEN Qiagen announces FDA clearance of QIAstat-Dx Rise
0 · Reply
Estimize
Estimize Aug. 6 at 8:00 PM
Wall St is expecting 0.58 EPS for $QGEN Q3 [Reporting 11/04 AMC] http://www.estimize.com/intro/qgen?chart=historical&metric_name=eps&utm_co
0 · Reply
OptionRunners
OptionRunners Jul. 24 at 4:43 PM
$QGEN Trader sold (to close) the August 15th $50 calls 1,350 times for $2.40 and bought (to open) the November 21st $55 calls 1,350 times for $1.80. The trader is rolling the calls out and up for a $0.60 credit
0 · Reply
JarvisFlow
JarvisFlow Jun. 26 at 5:56 PM
B of A Securities has updated their rating for Qiagen ( $QGEN ) to Buy with a price target of 53.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 19 at 3:39 PM
Kalorama's latest IVD report spotlights $QGEN alongside Roche and Abbott as key players driving infectious disease testing innovation. With new products targeting STIs and sepsis, Qiagen's digital PCR tech could capitalize on the $12B molecular diagnostics market. That 108x trailing P/E still needs some heavy lifting though. https://www.prnewswire.com/news-releases/infectious-disease-testing-market-remains-dynamic-amid-post-pandemic-shifts-and-new-innovations-302485467.html
0 · Reply
Latest News on QGEN
Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis

Aug 21, 2025, 9:52 AM EDT - 6 weeks ago

Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis


Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 1:44 PM EDT - 2 months ago

Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript


QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast

Jul 8, 2025, 5:44 AM EDT - 3 months ago

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast


Qiagen and Gencurix Enter Clinical Diagnostics Partnership

Jun 18, 2025, 4:38 PM EDT - 3 months ago

Qiagen and Gencurix Enter Clinical Diagnostics Partnership


Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:48 PM EDT - 5 months ago

Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript


QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

Apr 8, 2025, 11:22 AM EDT - 6 months ago

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast


QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

Mar 31, 2025, 6:00 AM EDT - 6 months ago

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results


Qiagen N.V.: Some Clarity Needed Before Buying The Dip

Feb 25, 2025, 4:39 PM EST - 7 months ago

Qiagen N.V.: Some Clarity Needed Before Buying The Dip


Qiagen N.V. (QGEN) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 4:49 PM EST - 8 months ago

Qiagen N.V. (QGEN) Q4 2024 Earnings Call Transcript


QIAGEN delivers solid Q4 2024 growth ahead of outlook

Feb 5, 2025, 4:05 PM EST - 8 months ago

QIAGEN delivers solid Q4 2024 growth ahead of outlook


QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

Jan 15, 2025, 8:13 AM EST - 9 months ago

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast


ZacksResearch
ZacksResearch Sep. 15 at 1:35 PM
$QGEN secures key CE-IVDR certification — will the stock’s momentum continue? 🚀 QIAGEN’s expanded QIAstat-Dx Panel broadens CNS infection coverage with 16 targets, strengthening its Molecular Diagnostics biz. The launch of this enhanced panel is expected in September 2025. With a 5% earnings yield against the industry’s -22.8%, it’s a promising outlook. Discover the potential impact on QGEN here 👉 https://www.zacks.com/stock/news/2751329/qgen-stock-gains-from-ce-ivdr-certification-for-qiastat-dx-portfolio?cid=sm-stocktwits-2-2751329-body-12357&ADID=SYND_STOCKTWITS_TWEET_2_2751329_BODY_12357
0 · Reply
ZacksResearch
ZacksResearch Sep. 15 at 12:35 PM
$QGEN just got a major boost 🚀 The full QIAstat-Dx portfolio is now CE-IVDR certified — strengthening its diagnostics arm and giving the stock a lift. See why this certification could be a game-changer 👉 https://www.zacks.com/stock/news/2751329/qgen-stock-gains-from-ce-ivdr-certification-for-qiastat-dx-portfolio?cid=sm-stocktwits-2-2751329-teaser-12355&ADID=SYND_STOCKTWITS_TWEET_2_2751329_TEASER_12355
0 · Reply
nikitatrades
nikitatrades Sep. 11 at 1:41 PM
$QGEN CFO: Strong H1 growth (6-7%) outpacing tools sector. Raising FY guidance. Key products QuantiFERON (20+ qtrs double-digit growth) & QIAstat driving performance. New sample prep launches (QIAsymphony Connect) coming. Margin target (31%) likely achieved by '26, ahead of schedule. 🧪 #Qiagen #Investing
0 · Reply
ZacksResearch
ZacksResearch Sep. 3 at 2:21 PM
$QGEN launches QIAstat-Dx Rise — enhancing diagnostics capabilities! 🚀 The FDA-cleared system offers automated, real-time PCR detection with minimal hands-on time, boosting testing capacity for hospitals and labs. With shares edging up 0.9% post-announcement, this momentum could continue. Discover how QGEN is expanding its diagnostics reach 👉 https://www.zacks.com/stock/news/2746540/qiagen-stock-may-benefit-from-the-us-clearance-of-qiastat-dx-rise?cid=sm-stocktwits-2-2746540-body-10705&ADID=SYND_STOCKTWITS_TWEET_2_2746540_BODY_10705
0 · Reply
ZacksResearch
ZacksResearch Sep. 3 at 1:20 PM
$QGEN could be gearing up for a catalyst move 🚀 The stock may benefit as the QIAstat-Dx Rise just secured US clearance — a major regulatory milestone. See the full investment angle here 👉 https://www.zacks.com/stock/news/2746540/qiagen-stock-may-benefit-from-the-us-clearance-of-qiastat-dx-rise?cid=sm-stocktwits-2-2746540-teaser-10664&ADID=SYND_STOCKTWITS_TWEET_2_2746540_TEASER_10664
0 · Reply
DonCorleone77
DonCorleone77 Sep. 2 at 10:23 AM
$QGEN Qiagen announces FDA clearance of QIAstat-Dx Rise
0 · Reply
Estimize
Estimize Aug. 6 at 8:00 PM
Wall St is expecting 0.58 EPS for $QGEN Q3 [Reporting 11/04 AMC] http://www.estimize.com/intro/qgen?chart=historical&metric_name=eps&utm_co
0 · Reply
OptionRunners
OptionRunners Jul. 24 at 4:43 PM
$QGEN Trader sold (to close) the August 15th $50 calls 1,350 times for $2.40 and bought (to open) the November 21st $55 calls 1,350 times for $1.80. The trader is rolling the calls out and up for a $0.60 credit
0 · Reply
JarvisFlow
JarvisFlow Jun. 26 at 5:56 PM
B of A Securities has updated their rating for Qiagen ( $QGEN ) to Buy with a price target of 53.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 19 at 3:39 PM
Kalorama's latest IVD report spotlights $QGEN alongside Roche and Abbott as key players driving infectious disease testing innovation. With new products targeting STIs and sepsis, Qiagen's digital PCR tech could capitalize on the $12B molecular diagnostics market. That 108x trailing P/E still needs some heavy lifting though. https://www.prnewswire.com/news-releases/infectious-disease-testing-market-remains-dynamic-amid-post-pandemic-shifts-and-new-innovations-302485467.html
0 · Reply
swingingtech
swingingtech Jun. 19 at 2:14 PM
$QGEN https://wallstreetwaves.com/potential-stock-surge-for-qiagen-following-new-qiacuity-dpcr-ivd-partnership-with-gencurix/
0 · Reply
ZacksResearch
ZacksResearch Jun. 17 at 4:35 PM
$INCY surges 5.1% on global partnership news Incyte partners with $QGEN to develop a diagnostic panel for its MPN treatments, strengthening its precision medicine strategy. Year to date, INCY is up 3.1% vs. industry’s 0.9% decline. Discover how this deal might impact INCY's growth 👉 https://www.zacks.com/commentary/2507024/incyte-stock-rises-on-qiagen-deal-to-advance-blood-cancer-diagnostics?cid=sm-stocktwits-2-2507024-body&ADID=SYND_STOCKTWITS_TWEET_2_2507024_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 16 at 1:16 PM
$QGEN partners with $INCY — a game-changer for onco-hematology diagnostics? 🤔 ⚕️ New collab to develop NGS panels for blood cancer gene detection 📊 QGEN's earnings yield of 5% vs. industry’s -29.4% is impressive 🚀 Shares up 4.7% over the past year against the industry’s 12.7% decline Discover how this could boost QGEN's market sentiment 👉 https://www.zacks.com/commentary/2503105/qgen-stock-rises-in-after-market-following-partnership-with-incyte?cid=sm-stocktwits-2-2503105-body&ADID=SYND_STOCKTWITS_TWEET_2_2503105_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 16 at 11:58 AM
$QGEN pops after hours on new Incyte partnership — here's why it matters 👀 The two are teaming up to develop NGS-based companion diagnostics targeting blood cancers — a high-value, high-growth niche. Full details on the partnership here 👉 https://www.zacks.com/stock/news/2503105/qgen-stock-rises-in-after-market-following-partnership-with-incyte?cid=sm-stocktwits-2-2503105-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2503105_TEASER
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 16 at 4:07 AM
Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism $INCY $QGEN https://stocktwits.com/news/equity/markets/retail-investors-flock-to-incyte-as-drug-data-qiagen-deal-fuel-optimism/chlnXq1RRbv
0 · Reply
DonCorleone77
DonCorleone77 Jun. 16 at 12:37 AM
$QGEN $INCY $ILMN Qiagen, Incyte announce collaboration to develop companion diagnostics QIAGEN (QGEN) and Incyte (INCY) announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms, a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin, which is being developed in myelofibrosis and essential thrombocythemia. Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions.
0 · Reply
ZacksResearch
ZacksResearch Jun. 13 at 5:45 PM
$QGEN outpaces the industry, but can it keep up the momentum? 📈 With a Zacks Rank #2 and a 8.9% gain in the past year against a 13.3% industry decline, QIAGEN is thriving on strategic R&D investments, partnerships, and solid solvency. Yet, macroeconomic headwinds and fierce competition could pose challenges. Opportunity assessment here 👉 https://www.zacks.com/commentary/2498546/should-you-add-qiagen-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2498546-body&ADID=SYND_STOCKTWITS_TWEET_2_2498546_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 13 at 4:22 PM
$QGEN holding steady through headwinds — but is it enough? Test menu expansion, key partnerships, and solid solvency are helping QGEN stay resilient in a tough macro environment. Fundamental insights here 👉 https://www.zacks.com/stock/news/2498546/should-you-add-qiagen-stock-to-your-portfolio-for-now?cid=sm-stocktwits-2-2498546-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2498546_TEASER
0 · Reply
ZacksResearch
ZacksResearch Jun. 3 at 1:19 PM
$QGEN strengthens its position in oncology diagnostics with new partnerships! 🔬 🧬 Collaborations with Tracer Biotechnologies and Foresight Diagnostics set to advance MRD testing. 📉 Despite a slight stock dip, QIAGEN's strategic moves aim to bolster its market position. Discover why this could boost market sentiment for QGEN 👉 https://www.zacks.com/commentary/2482253/qgen-stock-to-gain-from-expanding-oncology-portfolio-via-new-alliances?cid=sm-stocktwits-2-2482253-body&ADID=SYND_STOCKTWITS_TWEET_2_2482253_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 3 at 11:10 AM
$QGEN quietly building a moat in oncology? New MRD testing alliances are expanding its portfolio and reinforcing its push into personalized cancer care — a long-term growth lever. Full breakdown here 👉 https://www.zacks.com/stock/news/2482253/qgen-stock-to-gain-from-expanding-oncology-portfolio-via-new-alliances?cid=sm-stocktwits-2-2482253-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2482253_TEASER
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jun. 2 at 5:03 PM
$QGEN Foresight Diagnostics Partners With QIAGEN To Develop, Commercialize Kit-Based Version Of CLARITY Assay For Lymphoma
0 · Reply
ZacksResearch
ZacksResearch May. 23 at 1:13 PM
$QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership. Read the full story here: https://www.zacks.com/stock/news/2476645/qgen-stock-might-gain-following-new-partnership-with-id-solutions?cid=sm-stocktwits-2-2476645-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2476645_TEASER
0 · Reply